Medpace Holdings, Inc. (MEDP) Price Target Analysis
Wall Street analyst price targets, ratings consensus & upside potential · Updated May 1, 2026
Current Price
$426.79
Price Target
$498.86
Target Range
$400.00 — $582.00
Analyst Rating
Hold
Forward P/E25.1x
Trailing P/E27.9x
Forward PEG0.79
Implied Growth+6.9%
Median Target$484.00
Analyst Spread36.5%
Price Forecast (1 Year)
Last 12 months price action with 12-month analyst target path
Bear Case
$400
-6.3%
Consensus
$499
+16.9%
Bull Case
$582
+36.4%
Valuation Model TargetsConfidence: 74/100
Bear$360
Base$686
Bull$968
MEDP Price Target Analysis
Updated May 6, 2026As of May 6, 2026, Medpace Holdings, Inc. (MEDP) has a Wall Street consensus price target of $498.86, based on estimates from 19 covering analysts. With the stock currently trading at $426.79, this represents a potential upside of +16.9%. The company has a market capitalization of $12.19B.
Analyst price targets range from a low of $400.00 to a high of $582.00, representing a 36% spread in expectations. The median target of $484.00 aligns closely with the consensus average.
The current analyst consensus rating is Hold, with 6 analysts rating the stock as a Buy or Strong Buy,12 rating it Hold, and 1 rating it Sell or Strong Sell. The mixed ratings reflect uncertainty about near-term direction.
From a valuation perspective, MEDP trades at a trailing P/E of 27.9x and forward P/E of 25.1x. The forward PEG ratio of 0.79 suggests the stock may be undervalued relative to its growth. Analysts expect EPS to grow +6.9% over the next year.
Our proprietary valuation model, which blends historical multiples with forward estimates, suggests a base-case price target of $686.36, with bear and bull scenarios of $360.03 and $968.01 respectively. Model confidence stands at 74/100, indicating high predictability in the company's fundamentals.
Investment Context: Price targets represent analyst expectations for the next 12 months and should be considered alongside your own research. Targets are based on analysts' assumptions about earnings growth, margins, and market conditions which may change. For sector-specific context, view other Healthcare stocks.
Analyst Sentiment Comparison
Industry Peer AnalysisAvg Peer Upside+31.7%
Avg Forward P/E22.3x
Peers with Coverage10 / 10
| Company | Market Cap | Price | Target | Upside | Rating | Fwd P/E | Analysts |
|---|---|---|---|---|---|---|---|
 ICLRICON Public Limited Company | $9.5B | $124.13 | $149.63 | +20.5% | Buy | 10.5x | 30 |
 CRLCharles River Laboratories International, Inc. | $9.0B | $181.73 | $205.43 | +13.0% | Buy | 16.4x | 36 |
 PRAProAssurance Corporation | $1.3B | $24.60 | $18.33 | -25.5% | Hold | 21.8x | 11 |
 HIMSHims & Hers Health, Inc. | $6.9B | $26.88 | $29.67 | +10.4% | Hold | 53.9x | 19 |
 IQVIQVIA Holdings Inc. | $29.9B | $176.47 | $225.63 | +27.9% | Buy | 13.9x | 44 |
 NVCRNovoCure Limited | $1.9B | $16.50 | $33.50 | +103.1% | Buy | — | 15 |
 TMOThermo Fisher Scientific Inc. | $175.8B | $472.95 | $654.67 | +38.4% | Buy | 19.0x | 42 |
 DHRDanaher Corporation | $123.8B | $174.92 | $247.00 | +41.2% | Buy | 20.7x | 42 |
 BIOBio-Rad Laboratories, Inc. | $7.0B | $259.02 | $312.50 | +20.6% | Buy | 25.2x | 14 |
 VEEVVeeva Systems Inc. | $27.2B | $167.29 | $280.10 | +67.4% | Buy | 18.9x | 42 |
Upside Potential Comparison
NVCRVEEVDHRTMOIQVBIOICLRCRLFull MEDP Stock Analysis
Analyst consensus, bull case, AI-generated risk factors, and peer comparison — all in one place.
See MEDP's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs MEDP Undervalued?
DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationCompare MEDP vs DBVT
Side-by-side business, growth, and profitability comparison vs DBV Technologies S.A..
Start ComparisonMEDP — Frequently Asked Questions
Quick answers to the most common questions about buying MEDP stock.
What is the MEDP stock price target for 2026?
Medpace Holdings, Inc. (MEDP) has a consensus 12-month price target of $498.86, implying 16.9% upside from $426.79. The 19 analysts covering MEDP see moderate appreciation potential.
Is MEDP a buy, sell, or hold?
MEDP has a consensus rating of "Hold" based on 19 Wall Street analysts. The rating breakdown is mixed, with 12 Hold ratings making up the largest segment. The consensus 12-month price target of $498.86 implies 16.9% upside from current levels.
Is MEDP stock overvalued or undervalued?
MEDP trades at a forward P/E of 25.1264x, representing a moderate valuation. With analysts targeting $498.86 (16.9% implied move), the stock appears reasonably valued with upside.
How high can MEDP stock go?
The most bullish Wall Street analyst has a price target of $582 for MEDP, while the most conservative target is $400. The consensus of $498.86 represents the median expectation. Our quantitative valuation model projects a bull case target of $968 based on optimistic growth and margin assumptions. These targets typically reflect 12-month expectations.
How many analysts cover MEDP stock?
MEDP is well covered by analysts, with 19 analysts providing price targets and ratings. Of these, 0 have Strong Buy ratings, 6 have Buy ratings, 12 recommend Hold, and 1 have Sell or Strong Sell ratings. Higher analyst coverage generally indicates greater institutional interest and more reliable consensus estimates.
What is the MEDP stock forecast?
The 12-month MEDP stock forecast based on 19 Wall Street analysts shows a consensus price target of $498.86, with estimates ranging from $400 (bear case) to $582 (bull case). The median consensus rating is "Hold". Our proprietary valuation model produces a base case fair value of $686, with bear/bull scenarios of $360/$968.
What is MEDP's fair value based on fundamentals?
Our quantitative valuation model calculates MEDP's fair value at $686 (base case), with a bear case of $360 and bull case of $968. The model uses discounted cash flow analysis, historical growth rates, and margin mean-reversion to project FY+2 earnings, then applies an appropriate P/E multiple. The model confidence score is 74/100.
What is MEDP's forward P/E ratio?
MEDP trades at a forward P/E ratio of 25.1x based on next-twelve-months earnings estimates compared to a trailing P/E of 27.9x. The lower forward P/E indicates analysts expect earnings growth. A forward P/E is useful for comparing valuations when earnings are expected to change significantly.
Should I buy MEDP stock?
Wall Street analysts are optimistic on MEDP, with a "Hold" consensus rating and $498.86 price target (16.9% upside). 6 of 19 analysts rate it Buy or Strong Buy. This information is for educational purposes only. Always conduct your own research, consider your financial situation, and consult a financial advisor before making investment decisions.
Why do MEDP price targets vary so much?
MEDP analyst price targets range from $400 to $582, a 36% moderate spread showing some variance in outlooks. Differences stem from varying assumptions about revenue growth, profit margins, competitive dynamics, and valuation multiples. The $498.86 consensus represents the middle ground. Our model's $360-$968 range provides an independent fundamental perspective.